Abstract: This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homosubstitution.

Abstract: The invention relates to the use of compounds of a general formula (I), wherein R2, R14 to R17 and X groups have the following significance: R2 is C1-C5-Alkyl, C1-C5-Alkoxy or a —O—C<SB>N</SB>FmHo rest, wherein n=1,2,3,4,5 or 6, m>1 and m+o=2n+1, R14 and R15 separately designate hydrogen or together a methyl group or a supplementary liaison, R16 is hydrogen; R17 is hydrogen, hydroxy, C1-C5-Alkyl, C1-C5-Alkoxy or SO3NHX; X is hydrogen, C1-C5-alkyl or C1-C5 acyl. In the cycle B and D of a steroid skeleton, stippled lines can additionally represent up to two double bonds. The salts of said compounds which are pharmaceutically acceptable for preparing a drug are also disclosed.

Abstract: The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament Said compounds have an anti-tumour action.

Abstract: This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homosubstitution. They have a special action with respect to tubulin polymerization inhibition and can be used, for example, for treating prostate cancer.

Abstract: Hydrocarbon fluids are provided which have ASTM D-86 boiling point ranges within 235° C. to 400° C. and a naphthenic content greater than 60%, the naphthenics containing polycyclic materials, the fluids preferably have an aromatic content below 2% and an aniline point below 100° C. The fluids are particularly useful solvents for printing inks, drilling fluids, metal working fluids and as silicone extenders.

Abstract: The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17?-hydroxy steroid dehydro-genase type 1.

Abstract: The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of general formula I in which R2 means a saturated or unsaturated C1-C8-alkyl group, a C1-C5-alkyloxy group, an aralkyl radical or alkylaryl radical, a radical —O—CnFmHo, whereby n=1, 2, 3, 4, 5 or 6, m?1 and m+o=2n+1, or a group CH2XY, in which X stands for an oxygen atom and Y stands for an alkyl radical with 1 to 4 carbon atoms, as well as a halogen atom or a nitrile group, R13 means a hydrogen atom or a methyl group, R16 means a hydrogen atom or a fluorine atom, Z means an oxygen atom or a sulfur atom, R3 and R5, in each case independently of one another, mean an ?- or ?-position hydrogen atom, R4 and R6, in each case independently of one another, mean an ?- or ?-position hydrogen atom, a C1-C5-alkyl group, a C1-C5-alkyloxy group, a C1-C5-acyl group or a hydroxy group or an aralkyl radical or alkylaryl radical, R3 and R4 together mean an oxygen atom, R5 and R6 together mean an oxygen atom, R7 and R8 in each case mean a

Abstract: A flow pipe and one or more permanent magnets placed in or on the flow pipe, each permanent magnet presenting at its axial ends an infinite divergence of the magnetic field it generates. Fluid is treated by flowing through a flow pipe equipped with at least one such permanent magnet. The permanent magnet can be made of a plastic coextrudate with a ferromagnetic material such as iron powder, iron dust or iron chips. The permanent magnets can be arranged in groups with flow turbulence initiators positioned within the flow pipe between the magnet groups.

Abstract: The present invention relates to the use of the ER? agonists 8?-Vinyl-estra-1,3,5(10)-trien-3,17?-diol and 17?-Fluor-9?-vinyl-estra-1,3,5(10)-trien-3,16?-diol for production of medicaments for the prevention and/or treatment of hypertensive heart disease, especially for the prevention and/or treatment of one or more of the conditions selected from the group of (1) hypertension, (2) cardiac hypertrophy and (3) heart failure.

Abstract: This invention relates to 8?-vinyl-11?-(?-substituted)alkyl-estra-1,3,5(10)-trienes of general formula I with ER?-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations that contain the compounds according to the invention, as well as their use for the production of pharmaceutical agents. The new compounds can be used for contraception in men and women without influencing other estrogen-sensitive organs such as the uterus or the liver. They are also suitable for treating benign or malignant proliferative diseases of the ovary, such as ovarian cancer and granulosa cell tumors.

Abstract: The present invention discloses the use of ER?-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ER?-agonists are used for treatment of infertility and ER?-antagonists for contraception.

Abstract: A flow pipe and one or more permanent magnets placed in or on the flow pipe, each permanent magnet presenting at its axial ends an infinite divergence of the magnetic field it generates. Fluid is treated by flowing through a flow pipe equipped with at least one such permanent magnet. The permanent magnet can be made of a plastic coextrudate with a ferromagnetic material such as iron powder, iron dust or iron chips. The permanent magnets can be arranged in groups with flow turbulence initiators positioned within the flow pipe between the magnet groups.

Abstract: The present invention discloses the use of ER&bgr;-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ER&bgr;-agonists are used for treatment of infertility and ER&bgr;-antagonists for contraception.

Abstract: This invention describes the new 8&bgr;-substituted estratrienes of general formula (I),

Abstract: Hydrocarbon fluids are provided which have ASTM D-86 boiling point ranges within 235° C. to 400° C. and a naphthenic content greater than 60%, the naphthenics containing polycyclic materials, the fluids preferably have an aromatic content below 2% and an aniline point below 100° C. The fluids are particularly useful solvents for printing inks, drilling fluids, metal working fluids and as silicone extenders.

Abstract: This invention describes the new 8&bgr;-substituted estratrienes of general formula I in which R2, R3, R6, R6′, R7, R7′, R9, R11, R11′, R12, R14, R15, R15′, R16, R16′, R17 and R17′ have the meanings that are indicated in the description, and R8 means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.

Abstract: This invention relates to 11&bgr;-(para-substituted)phenyl-estra-1,3,5(10)-trienes with a straight-chin or branched-chain, optionally partially or completely halogenated alkyl radical or alkenyl radical in each case with up to 5 carbon atoms, an ethinyl radical or prop-1-inyl radical in 8&bgr;-position.

Abstract: This invention describes the use of estrogen receptor (ER)&bgr;-selective agonists for the production of a pharmaceutical agent for triggering somatotropic and/or organotropic effects in the CNS, the circulatory system, the skeletal system and/or the immune system in the aging male and female organism (anticatabolic therapy).

Abstract: The invention relates to new C13-substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, wherein R1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R15 represents ethyl, methods of preparing same, and pharmaceutical compositions containing these compounds. The compounds of the invention of general formula I inhibit the activity of steroid sulfatase (EC 3.1.6.2) and do not exhibit any estrogenic effect.

Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I 1